Boston Scientific Corporation BSX-PA NYSE

Boston Scientific Corporation (BSX-PA) reported total assets of $43.67B and total liabilities of $19.2B for fiscal year 2025, resulting in total equity of $24.47B.

The company held $2.05B in cash and short-term investments. Total debt stood at $12.42B, with net debt of $10.37B. The Debt-to-Equity (D/E) ratio was 0.51 (moderate).

Current ratio is 1.62, indicating strong short-term liquidity. Interest coverage is 11.4x (strong).

Criteria supported by this page:

• HEALTH (83/100, Pass) — Debt-to-Equity of 0.51, current ratio of 1.62, interest coverage 11.4x — balance sheet is strong
• MOAT (86/100) — Total assets $43.67B and equity $24.47B support the company's competitive scale
• VALUE (15/100) — Debt-to-Equity 0.51 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 76/100 with 5/7 criteria passed.

C-PK

Citigroup Inc.

$24.99

-0.04%

APTV-PA

Aptiv PLC

$108.66

+0.15%

BDXB

Becton, Dickinson and Company

$48.16

+1.39%

CFG-PE

Citizens Financial Group, Inc.

$19.03

+0.32%

DLR-PL

Digital Realty Trust, Inc.

$19.87

+0.65%

LLY

Eli Lilly and Company

$922.50

-0.76%

JNJ

Johnson & Johnson

$240.10

+0.90%

ABBV

AbbVie Inc.

$210.32

+1.86%